GlassScriptPhysician profile
Mark Bryniarski
NPI 1528063161
$4,297.71
in general payments reported to CMS, 2019-2025
47 companies · $1,577 in 2025
The $1,577 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $176 · 2021: $77.08 · 2022: $301 · 2023: $701 · 2024: $987 · 2025: $1,577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,265.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $549.11 | 2019-2025 | Rystiggo, Zilbrysq, Nayzilam |
| Acadia Pharmaceuticals INC | $352.19 | 2023-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $308.05 | 2023-2025 | Ultomiris |
| Genentech USA, INC. | $277.03 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Inspire Medical Systems, INC. | $235.88 | 2025 | Inspire |
| Abbvie INC. | $210.63 | 2023-2025 | Botox, Rinvoq |
| Portola Pharmaceuticals, LLC | $169.13 | 2019-2020 | |
| Lilly USA, LLC | $164.62 | 2020-2025 | Emgality, Reyvow, Amyvid |
| Argenx US, INC. | $152.99 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurocrine Biosciences, INC. | $128.58 | 2019-2025 | Ingrezza, Ongentys |
| Aesculap, INC. | $114.27 | 2019-2021 | |
| Csl Behring | $105.56 | 2021-2025 | Hizentra |
| Novartis Pharmaceuticals Corporation | $91.24 | 2019-2025 | |
| Globus Medical, INC. | $91.14 | 2022 | |
| Sk Life Science, INC. | $90.92 | 2023-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $79.96 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Alphatec Spine, INC | $79.49 | 2022 | |
| Medtronic, INC. | $71.37 | 2022 | |
| Merz Pharmaceuticals, LLC | $60.21 | 2024-2025 | Inbrija, Xeomin |
| Neurelis, INC. | $58.23 | 2024-2025 | Valtoco |
| Lundbeck LLC | $57.75 | 2025 | Vyepti |
| Jazz Pharmaceuticals INC. | $55.82 | 2023-2024 | |
| Eisai INC. | $52.64 | 2023-2025 | |
| Grifols USA, LLC | $51.71 | 2024 | Gamunex-C |
| Amgen INC. | $49.72 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $48.58 | 2024-2025 | Rexulti |
| Biogen, INC. | $46.82 | 2023-2025 | Vumerity, Tysabri |
| Orthofix Medical, INC. | $44.91 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $44.12 | 2025 | |
| Gt Medical Technologies, INC | $42.79 | 2025 | Gammatile |
| Ge Healthcare | $40.52 | 2019-2025 | |
| Nuvasive, INC. | $39.37 | 2020 | |
| Tanabe Pharma America, INC. | $37.20 | 2019-2023 | |
| Stryker Corporation | $33.45 | 2024 | Adherus Autospray Dural Sealant, Duramatrix |
| Banner Life Sciences, LLC | $30.29 | 2024 | |
| Janssen Biotech, INC. | $29.73 | 2025 | |
| Mimedx Group, INC. | $25.31 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.69 | 2023 | Entyvio |
| Acorda Therapeutics, INC | $23.88 | 2019 | |
| Lemaitre Vascular, INC. | $23.15 | 2019 | |
| Cerapedics INC. | $19.91 | 2022 | |
| Genzyme Corporation | $15.56 | 2023 | |
| Abbott Laboratories | $15.25 | 2022 | |
| Cycle Pharmaceuticals INC | $14.64 | 2025 | Tascenso Odt, Bafiertam |
| Ipsen Biopharmaceuticals, INC | $13.73 | 2025 | Iqirvo |
| Vertex Pharmaceuticals Incorporated | $13.69 | 2025 | |
| Horizon Therapeutics Plc | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bryniarski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.